选择性CDK抑制剂创伤性脑损伤未来临床试验中有希望的候选药物.docVIP

选择性CDK抑制剂：创伤性脑损伤未来临床试验中有希望的候选药物 选择性细胞周期蛋白依赖性激酶抑制剂：创伤性脑损伤未来临床试验中有希望的候选药物 创伤性脑损伤会因为神经炎症，神经元缺失和神经功能障碍引发继发性损伤。其中一中重要的损伤机制就是细胞周期激活可引起神经细胞和神经胶质细胞凋亡的激活。非选择性和选择性细胞周期蛋白依赖性激酶抑制剂的神经保护作用已被应用于多个创伤性脑损伤实验模型的治疗之中。细胞周期蛋白依赖性激酶是一类重要的丝氨酸/苏氨酸蛋白激酶，主要生物学作用是以复合物形式出现启动DNA的复制和诱发细胞的有丝分裂。 来自美国马里兰大学医学院Alan I. Faden教授所在实验室在创伤性脑损伤24小时后，证明了系统性单次给予抑制剂量能够减少神经元细胞死亡，抗神经炎症和神经功能障碍提供极强的神经保护作用。鉴于其有效性和长期治疗窗，细胞周期蛋白依赖性激酶抑制剂似乎是脑外伤临床试验被认为颇具前景的候选干预方法。相关研究内容发表在2014年9月第17期《中国神经再生研究（英文版）》杂志上。 Article: Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials by Shruti V. Kabadi, Alan I. Faden Department of Anesthesiology, Center for Shock, Trauma and Anesthesiology Research STAR , University of Maryland School of Medicine, Baltimore, MD, USA Kabadi SV, Faden AI. Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials. Neural Regen Res. 2014;9 17 :1578-1580. 欲获更多资讯： Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials Traumatic brain injury TBI induces secondary injury that contributes to neuroinflammation, neuronal loss, and neurological dysfunction. One important injury mechanism is cell cycle activation which causes neuronal apoptosis and glial activation. The neuroprotective effects of both non-selective Flavopiridol and selective Roscovitine and CR-8 cyclin-dependent kinase CDK inhibitors have been shown across multiple experimental TBI models and species. Prof. Alan I. Faden, who comes from University of Maryland School of Medicine, and his colleague administered CDK inhibitors, as a single systemic dose up to 24h after TBI, provide strong neuroprotectionreducing neuronal cell death, neuroinflammation and neurological dysfunction. Given their effectiveness and long therapeutic window, CDK inhibitors appear to be promising candidates for clinical TBI trials. The relevant study has been published in the Neural Regeneration Research Vol. 9, No. 17, 2014 . Article: Selective CD